Compare PDLB & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | OVID |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 562.5M |
| IPO Year | 2021 | 2017 |
| Metric | PDLB | OVID |
|---|---|---|
| Price | $20.56 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 58.1K | ★ 1.3M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 3.90 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | $28.66 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $13.91 | $1.18 |
| 52 Week High | $21.10 | $3.11 |
| Indicator | PDLB | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 47.90 |
| Support Level | $19.66 | $2.60 |
| Resistance Level | $20.81 | $2.77 |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 75.27 | 25.00 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.